2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerBiliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, biliary tract cancer, biliary tract disorder, carcinoma, cholangiocarcinoma, epithelial neoplasm, gallbladder disorder, gallbladder neoplasm, neoplasmRecruitingPhase 32026-09-14NCT06282575
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinomaActive, not recruitingPhase 32026-07-22NCT05911295